Kilter Group’s Haemonetics HAE Stock Holding History

Kilter Group’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-12	Closed	-$585	–	1439
2025 Q3	$585	Hold	12	–	–	﹤0.01%	1015
2025 Q2	$896	Buy	+12	New	+$795	﹤0.01%	848

Other funds holding HAE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Holocene Advisors New York $44.4B AUM 57.89% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Kilter Group's HAE Position: Q4 2025 in Review

Kilter Group sold out of Haemonetics (HAE) in Q4 2025, closing a stake of 12 shares — an estimated $585 sold.

Kilter Group first reported a position in HAE in Q2 2025 and held it in 2 quarters. The position peaked at $896 in Q2 2025. 329 funds tracked by Wall St. Rank hold HAE as of Q4 2025.

Kilter Group reported no remaining Haemonetics position as of Q4 2025 after selling out during the quarter.
Kilter Group sold 12 Haemonetics shares in Q4 2025, an estimated $585.
Kilter Group first reported a position in Haemonetics in Q2 2025 and held it in 2 quarters.
Kilter Group's Haemonetics position peaked at $896 in Q2 2025.
329 funds tracked by Wall St. Rank held Haemonetics as of Q4 2025.

Based on Kilter Group's 13F filing for Q4 2025, filed 13 Feb 2026.